Additional support for using CLEC12A as an immunotherapy target comes from a recent expression study in pediatric AML patients that showed that the combination of CD33 and CLEC12A was the most frequently upregulated one in pediatric AML samples, making it a potential therapeutic target with limited on-target off-leukemia side effects [71]. This evidence concerns the gene CD33 and acute myeloid leukemia.